JioBlackRock Gets Sebi Nod for Four Mutual Fund Schemes
You're reading Entrepreneur India, an international franchise of Entrepreneur Media.
JioBlackRock Asset Management, the joint venture between Jio Financial Services and global investment firm BlackRock, has received regulatory approval from the Securities and Exchange Board of India to launch four mutual fund schemes.
The approved offerings include the JioBlackRock Nifty 8–13 Yr G-Sec Index Fund, Nifty Smallcap 250 Index Fund, Nifty Next 50 Index Fund, and Nifty Midcap 150 Index Fund. Among these, three are equity-based index funds, while one is focused on government debt securities.
The company aims to tap into India's growing investor base with a digital-first approach that emphasises simplicity in fund offerings. This strategy aligns with models used by fintech firms like Zerodha, Groww, and Navi. With strong financial backing and access to a large user base, JioBlackRock is expected to bring increased competition to the market.
Nithin Kamath, founder of Zerodha, responded positively to the entry of JioBlackRock, suggesting it could help broaden India's investor base. He also reiterated Zerodha's commitment to long-term profitability and customer-focused services, noting that financial strength alone does not create enduring advantages in stockbroking.
Earlier this month, JioBlackRock completed its first new fund offer, raising INR 17,800 crore across three schemes. The offer attracted over 90 institutional investors and more than 67,000 retail investors in just three days.
In addition to mutual funds, Jio Financial is expanding into wealth management and stockbroking. It recently established Jio BlackRock Broking Pvt Ltd, which is awaiting regulatory clearance to begin operations.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
Those who invested in Sandfire Resources (ASX:SFR) three years ago are up 164%
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But in contrast you can make much more than 100% if the company does well. For example, the Sandfire Resources Limited (ASX:SFR) share price has soared 161% in the last three years. How nice for those who held the stock! It's also good to see the share price up 13% over the last quarter. But this could be related to the strong market, which is up 12% in the last three months. Let's take a look at the underlying fundamentals over the longer term, and see if they've been consistent with shareholders returns. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price. During three years of share price growth, Sandfire Resources moved from a loss to profitability. Given the importance of this milestone, it's not overly surprising that the share price has increased strongly. You can see below how EPS has changed over time (discover the exact values by clicking on the image). We know that Sandfire Resources has improved its bottom line lately, but is it going to grow revenue? Check if analysts think Sandfire Resources will grow revenue in the future. What About The Total Shareholder Return (TSR)? We've already covered Sandfire Resources' share price action, but we should also mention its total shareholder return (TSR). Arguably the TSR is a more complete return calculation because it accounts for the value of dividends (as if they were reinvested), along with the hypothetical value of any discounted capital that have been offered to shareholders. Dividends have been really beneficial for Sandfire Resources shareholders, and that cash payout contributed to why its TSR of 164%, over the last 3 years, is better than the share price return. A Different Perspective It's nice to see that Sandfire Resources shareholders have received a total shareholder return of 31% over the last year. That gain is better than the annual TSR over five years, which is 18%. Therefore it seems like sentiment around the company has been positive lately. Someone with an optimistic perspective could view the recent improvement in TSR as indicating that the business itself is getting better with time. If you would like to research Sandfire Resources in more detail then you might want to take a look at whether insiders have been buying or selling shares in the company. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Australian exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29 minutes ago
- Yahoo
Nvidia and Broadcom: Here's How These Top AI Stocks Are Doing 1 Year After Their Stock Splits
Key Points These leading AI players saw their shares skyrocket in the year prior to their stock splits, with levels reaching beyond $1,000. Nvidia and Broadcom both have reported soaring demand for their products. 10 stocks we like better than Nvidia › Stock splits were a big thing last year, with many major companies across industries launching such operations. Two of the most exciting were in the area of artificial intelligence (AI). Nvidia (NASDAQ: NVDA), the world's No. 1 AI chip designer, and Broadcom (NASDAQ: AVGO), a networking giant, completed stock splits in June and July 2024, respectively. What is a stock split, and why do companies go this route? These operations enable a company to bring down a soaring stock price to more reasonable levels, making the stock more accessible to a broader range of investors. Nvidia and Broadcom even said they decided on splits to make it easier for employees and investors to get in on their shares, which had surged more than 200% and about 100%, respectively, in 2023. Stock splits don't change the total market value of the company or anything fundamental, though. They simply involve offering more shares to current holders according to the ratio of the split. So, for example, in a 10-for-1 stock split, if you originally held one share, you would hold 10 shares post-split -- but the total value of your holding would remain the same. Because of this, a stock split alone isn't a reason to buy or sell a stock. Still, it's interesting to see how stock split players have performed a year after these operations, so let's take a look at both Nvidia and Broadcom a year after their splits. Nvidia Nvidia completed its 10-for-1 stock split on June 7 of last year, with shares trading at the split-adjusted price as of June 10. This brought the shares down from about $1,200 to $120. Since that time, Nvidia stock has experienced ups and downs, but it's delivered a gain of more than 40%. As mentioned, this operation isn't the reason investors have flocked to Nvidia over the past year (though a lower price per share may have made it easier for some to get in on the growth story). What has driven Nvidia's share price performance is the ongoing high demand for its graphics processing units (GPUs), or AI chips, and related products and services. What also helped this AI leader was its strong execution of a big launch: Nvidia released its Blackwell architecture and chip this past winter to demand that CEO Jensen Huang called "insane." The company generated $11 billion in revenue from Blackwell in its very first quarter of commercialization and maintained a gross margin above 70%, ensuring high profitability on sales. Although investors worried about potential headwinds, such as import tariffs or a decrease in AI spending, these concerns have eased. Trade talks have spurred optimism that tariffs may not be as hefty as initially expected, and companies have reiterated their AI investment plans. All of this helped boost Nvidia's shares in recent weeks, even pushing the company to a $4 trillion market cap, making it the first company ever to reach this level. Broadcom Broadcom executed its stock split on July 12, and the stock began trading on July 15 at the new price. Like Nvidia, the company decided on a 10-for-1 split to bring its share price down -- in this case, from about $1,700 to $170. Broadcom stock has also climbed in the double digits since the operation, rising more than 65%. And like Nvidia, Broadcom saw its shares take off thanks to demand from AI customers. This company is a networking leader, making thousands of products used in a variety of locations -- from your smartphone to major data centers. But in recent times, demand from big cloud service providers to support their AI development has helped revenue skyrocket. In the most recent quarter, AI revenue surged 77% to $4.1 billion, and the company says it expects this momentum to continue in the current quarter and through the next fiscal year. This is amid demand for both connectivity products and Broadcom's accelerated processing units (XPUs), a type of processor for specific AI tasks. The company says its networking expertise and wide range of products -- from switches and routers to network interface cards (NICs), which connect computers to networks -- have been key growth drivers as cloud service providers ramp up their AI platforms. Broadcom stock followed a similar path to Nvidia, declining in April of this year due to general tariff concerns, but it has also rebounded and is on the rise today. The stock even closed at a record high just a few days ago. Could the post-split success continue? Both Nvidia and Broadcom have completed successful post-split years, scoring double-digit gains. Nvidia is slightly less expensive from a valuation standpoint than it was a year ago, but Broadcom's valuation has advanced. Still, these AI players remain reasonably priced, considering their earnings track record and long-term prospects in this growth market. It's impossible, of course, to guarantee what these stocks will do next, but the current environment supports the idea of more gains ahead. Even more importantly, Nvidia and Broadcom are well positioned to win in the AI market over the long run. Should you buy stock in Nvidia right now? Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Nvidia. The Motley Fool recommends Broadcom. The Motley Fool has a disclosure policy. Nvidia and Broadcom: Here's How These Top AI Stocks Are Doing 1 Year After Their Stock Splits was originally published by The Motley Fool
Yahoo
32 minutes ago
- Yahoo
A Once-in-a-Lifetime Opportunity: This Blue Chip Healthcare Stock Down 50% Could Double Your Money
Key Points Novo Nordisk's recent financial results and clinical progress haven't impressed Wall Street. However, the company can right the ship through innovation in its core specialty and elsewhere. The stock looks attractively valued at current levels and could beat the market over the next six years. 10 stocks we like better than Novo Nordisk › Investors looking to strike while the iron is hot can buy beaten-down stocks that appear to have excellent chances of bouncing back. And that describes shares of Novo Nordisk (NYSE: NVO) very well. The pharmaceutical leader is down by 52% over the trailing-12-month period as of July 17, but initiating a position now could double investors' money in six years or so. Here's why this stock is a screaming buy at its current levels. Novo Nordisk's recent challenges Novo Nordisk focuses on developing diabetes treatments, an area where it has been a leader for many decades. As of February, it held a 33.3% market share for diabetes drugs. This sort of long-term dominance doesn't happen by accident. The company has consistently attracted top talent in the pharmaceutical industry, which, combined with its extensive experience in diabetes, has enabled it to break new ground repeatedly. Why, then, have the company's shares dropped by 52% over the past year? Because Novo Nordisk failed to impress the market with its financial results and clinical progress. The developments that led to the drugmaker's share plunge would have been excellent for almost any other pharmaceutical company, but investors held it to a higher standard given its rich valuation metrics. For instance, the company reported phase 3 results for CagriSema, an investigational weight management medicine, that proved it's more effective than its famous semaglutide (Wegovy), reducing patients' weight by an average of 22.7% in 68 weeks. However, management was looking for a 25% figure in the study. Very few anti-obesity therapies in development have achieved results comparable to CagriSema, but that was not enough to please investors. The good news: Novo Nordisk's pipeline in diabetes and the fast-growing area of weight management remains robust. The company has several promising candidates in development, including Amycretin, for which it recently initiated late-stage studies. And management has significantly expanded its pipeline through acquisitions. Even with mounting competition, the company should continue to be one of the leaders in its core areas of focus. It's been developing medicines in other fields as well, including various rare diseases (such as the blood disorders beta thalassemia and sickle cell disease), neurological disorders (including Alzheimer's and Parkinson's), and others. Making progress in diabetes and obesity while diversifying its lineup should work wonders for Novo Nordisk down the line. The price is right Net sales in the first quarter grew by 19% year over year to 78.1 billion Danish krone ($12.1 billion). The company's net profit was up 14% year over year to $4.5 billion. These would be excellent results for most similarly sized drugmakers, yet Wall Street remains unimpressed. In my view, that has created a wonderful opportunity to buy shares on the dip. The company's forward price-to-earnings ratio (P/E) has declined significantly over the past year and now stands at 16.9, barely above the healthcare industry's 16.2 and lower than the S&P 500's 22.3. But given Novo Nordisk's still excellent position in its core markets of diabetes and obesity treatments -- the latter of which should grow rapidly in the coming years -- and the company's better-than-average revenue and earnings growth, its stock is arguably worth a steeper premium. In fact, the forward P/E is about as low as it has been in over two years. At current levels, shares look like a steal. Here is how things could evolve for the company in the next six years. First, it could make significant clinical and regulatory progress and launch at least one -- if not several -- blockbuster weight loss or diabetes medications. Second, the company should continue recording strong results, with revenue and earnings moving in the right direction. Lastly, it looks likely to continue increasing its dividend, which it has done significantly over the past half-decade. The stock needs a compound annual growth rate of 12.2% to double in the next six years. Novo Nordisk can pull it off, especially for those who opt to reinvest the dividend. Should you buy stock in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 Prosper Junior Bakiny has positions in Novo Nordisk. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. A Once-in-a-Lifetime Opportunity: This Blue Chip Healthcare Stock Down 50% Could Double Your Money was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
